Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction

Pazopanib is an orally bioavailable tyrosine kinase inhibitor anticancer drug approved worldwide for the treatment of metastatic renal cell carcinoma and advanced soft tissue sarcoma. Here we report the case of a patient whose recurrent retroperitoneal soft tissue sarcoma showed a drastic reduction...

Descripción completa

Detalles Bibliográficos
Autores principales: Okubo, Kazuki, Horiguchi, Akio, Ito, Keiichi, Asano, Tomohiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041368/
https://www.ncbi.nlm.nih.gov/pubmed/30003043
http://dx.doi.org/10.1016/j.eucr.2018.05.018
_version_ 1783338980348002304
author Okubo, Kazuki
Horiguchi, Akio
Ito, Keiichi
Asano, Tomohiko
author_facet Okubo, Kazuki
Horiguchi, Akio
Ito, Keiichi
Asano, Tomohiko
author_sort Okubo, Kazuki
collection PubMed
description Pazopanib is an orally bioavailable tyrosine kinase inhibitor anticancer drug approved worldwide for the treatment of metastatic renal cell carcinoma and advanced soft tissue sarcoma. Here we report the case of a patient whose recurrent retroperitoneal soft tissue sarcoma showed a drastic reduction immediately after pazopanib administration accompanied by severe liver dysfunction. His liver function was restored conservatively by giving him hepatoprotectors and having him stop taking pazopanib. The recurrent tumor disappeared but by 4 months later had regrown.
format Online
Article
Text
id pubmed-6041368
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-60413682018-07-12 Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction Okubo, Kazuki Horiguchi, Akio Ito, Keiichi Asano, Tomohiko Urol Case Rep Oncology Pazopanib is an orally bioavailable tyrosine kinase inhibitor anticancer drug approved worldwide for the treatment of metastatic renal cell carcinoma and advanced soft tissue sarcoma. Here we report the case of a patient whose recurrent retroperitoneal soft tissue sarcoma showed a drastic reduction immediately after pazopanib administration accompanied by severe liver dysfunction. His liver function was restored conservatively by giving him hepatoprotectors and having him stop taking pazopanib. The recurrent tumor disappeared but by 4 months later had regrown. Elsevier 2018-06-06 /pmc/articles/PMC6041368/ /pubmed/30003043 http://dx.doi.org/10.1016/j.eucr.2018.05.018 Text en © 2018 The Authors. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Okubo, Kazuki
Horiguchi, Akio
Ito, Keiichi
Asano, Tomohiko
Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction
title Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction
title_full Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction
title_fullStr Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction
title_full_unstemmed Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction
title_short Recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction
title_sort recurrent retroperitoneal soft tissue sarcoma showing drastic reduction after pazopanib administration accompanied by severe liver dysfunction
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6041368/
https://www.ncbi.nlm.nih.gov/pubmed/30003043
http://dx.doi.org/10.1016/j.eucr.2018.05.018
work_keys_str_mv AT okubokazuki recurrentretroperitonealsofttissuesarcomashowingdrasticreductionafterpazopanibadministrationaccompaniedbysevereliverdysfunction
AT horiguchiakio recurrentretroperitonealsofttissuesarcomashowingdrasticreductionafterpazopanibadministrationaccompaniedbysevereliverdysfunction
AT itokeiichi recurrentretroperitonealsofttissuesarcomashowingdrasticreductionafterpazopanibadministrationaccompaniedbysevereliverdysfunction
AT asanotomohiko recurrentretroperitonealsofttissuesarcomashowingdrasticreductionafterpazopanibadministrationaccompaniedbysevereliverdysfunction

Ejemplares similares